HC Wainwright Reaffirms Buy Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating reissued by HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $20.00 target price on the stock.

Separately, Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a research note on Tuesday, August 13th.

Aprea Therapeutics Stock Up 1.3 %

Shares of NASDAQ APRE opened at $3.02 on Monday. The business’s 50 day moving average is $3.33 and its two-hundred day moving average is $3.86. Aprea Therapeutics has a 52-week low of $2.15 and a 52-week high of $8.85. The firm has a market cap of $16.41 million, a price-to-earnings ratio of -1.07 and a beta of 0.97.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. The firm had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.45 million. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. Analysts anticipate that Aprea Therapeutics will post -2.56 EPS for the current fiscal year.

Insider Buying and Selling at Aprea Therapeutics

In related news, Director Marc Duey acquired 30,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were bought at an average price of $4.39 per share, with a total value of $131,700.00. Following the completion of the acquisition, the director now owns 240,113 shares in the company, valued at $1,054,096.07. This trade represents a 14.28 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bernd R. Seizinger bought 10,000 shares of the stock in a transaction dated Friday, October 11th. The stock was bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the acquisition, the director now owns 44,730 shares in the company, valued at approximately $119,876.40. This represents a 28.79 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 42,290 shares of company stock worth $165,096 over the last ninety days. Corporate insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Stonepine Capital Management LLC bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics comprises about 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st largest holding. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.